Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

被引:9
作者
Dalhoff, Axel [1 ]
Schubert, Sabine [1 ]
机构
[1] Univ Hosp Schleswig Holstein, Inst Infect Med, D-24105 Kiel, Germany
关键词
Staphylococcus aureus; Fluoroquinolones; High-level oxacillin resistance; Dichotomous selection; FIBRONECTIN-BINDING PROTEINS; IN-VITRO ACTIVITY; METHICILLIN-RESISTANT; ANTIBACTERIAL ACTIVITY; METICILLIN-RESISTANT; SUBINHIBITORY LEVELS; RISK; MOXIFLOXACIN; PHARMACOKINETICS; PHARMACODYNAMICS;
D O I
10.1016/j.ijantimicag.2010.04.014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The objective of this study was to determine whether exposure of Staphylococcus aureus to early (ciprofloxacin or levofloxacin) and a recent fluoroquinolone (moxifloxacin) has differential potential as a mutator or selector for meticillin resistance. The potential of fluoroquinolones to act as mutators or selectors was studied in 24 strains each of healthcare-associated meticillin-susceptible S. aureus (MSSA) and meticillin-resistant S. aureus (MRSA) as well as 6 strains of community-acquired MRSA. Mutator or selector potential was studied first by exposing isolates to 0.5x the fluoroquinolone minimal inhibitory concentration (MIC) and screening for either single-step fluoroquinolone resistance or high-level oxacillin resistance; second, by exposing the heteroresistant MRSA P8 parent strain as well as fluoroquinolone-resistant subpopulations derived from strain P8 to constant fluoroquinolone concentrations ranging from 0.015 mg/L to 128 mg/L; and third, by exposing the heteroresistant MRSA population of strain P8 to fluctuating concentrations of ciprofloxacin, levofloxacin and moxifloxacin simulating oral doses of 500 mg twice a day, 500 mg once daily (qd) and 400 mg qd, respectively, compared with amoxicillin/clavulanic acid 500 mg three times a day. Total viable counts and subpopulations resistant to 2x, 4x and 8x the fluoroquinolone MICs and to 32, 64 and 128 mg/L oxacillin [high-level oxacillin (hl-OXA)-resistant] were quantitated. None of the fluoroquinolones acted as a mutator; ciprofloxacin and levofloxacin selected for hl-OXA resistance, whereas moxifloxacin selected towards hl-OXA resistance by one order of magnitude less frequently. The P8 parent and fluoroquinolone-resistant subpopulations were eliminated by ciprofloxacin or levofloxacin concentrations >10-fold higher than the MICs, whereas moxifloxacin eliminated all subpopulations by concentrations 2-3-fold the MIC. Finally, exposure of P8 to fluctuating amoxicillin/clavulanic acid, ciprofloxacin and levofloxacin concentrations, respectively, caused a rapid selection of fluoroquinolone and hl-OXA resistance. Moxifloxacin reduced total viable counts rapidly, thus preventing the emergence of resistant subpopulations. In conclusion, fluoroquinolones do not act as mutators towards hl-OXA resistance. However, ciprofloxacin and levofloxacin are potent selectors of hl-OXA resistance, whereas moxifloxacin is a poor selector. In contrast to ciprofloxacin and levofloxacin, moxifloxacin exerts a high bactericidal activity against staphylococci, thus minimising the probability for selection of resistance. Thus, fluoroquinolones exert a dichotomous MRSA-selective potential in heteroresistant MRSA. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:216 / 221
页数:6
相关论文
共 42 条
[1]  
[Anonymous], 2012, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard
[2]   Factors influencing methicillin resistance in staphylococci [J].
Berger-Bächi, B ;
Rohrer, S .
ARCHIVES OF MICROBIOLOGY, 2002, 178 (03) :165-171
[3]   Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin [J].
Bisognano, C ;
Vaudaux, PE ;
Lew, DP ;
Ng, EYW ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :906-913
[4]   Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin [J].
Bisognano, C ;
Vaudaux, P ;
Rohner, P ;
Lew, DP ;
Hooper, DC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1428-1437
[5]   Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals [J].
Crowcroft, NS ;
Ronveaux, O ;
Monnet, DL ;
Mertens, R .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (01) :31-36
[6]  
Dalhoff A, 2005, INFECTION, V33, P36, DOI [10.1007/s15010-005-8206-y, 10.1007/s15010-005-8206-Y]
[7]   Pharmacodynamics of fluoroquinolones [J].
Dalhoff, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :51-59
[8]   In vitro antibacterial activity and phamacodynamics of new quinolones [J].
Dalhoff, A ;
Schmitz, FJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (04) :203-221
[9]   In vitro activity of BAY 12-8039, a new 8-methoxyquinolone [J].
Dalhoff, A ;
Petersen, U ;
Endermann, R .
CHEMOTHERAPY, 1996, 42 (06) :410-425
[10]  
DALHOFF A, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1148